Login to Your Account



Kymab Lands First Kymouse Antibody Deal with Novo

By Cormac Sheridan
Staff Writer

Wednesday, April 24, 2013
Novo Nordisk A/S is the first taker for Kymab Ltd.'s second-generation transgenic mouse antibody platform Kymouse, providing all-important industry validation for the fledgling technology, as well license fees, development milestones and royalties on eventual product sales.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription